Literature DB >> 27335067

Intravenous Immunoglobulin Suppresses Abortion Relates to an Increase in the CD44bright NK Subset in Recurrent Pregnancy Loss Model Mice.

Jun Tanaka1, Akira Kitashoji2, Yuki Fukunaga2, Junichi Kashihara2, Atsushi Nakano2, Akihito Kamizono2.   

Abstract

Recurrent pregnancy loss (RPL), which mostly is of unknown etiology (unexplained RPL, uRPL), is defined as three or more consecutive spontaneous abortions. Some women with uRPL display a higher fraction and cytotoxicity of natural killer (NK) cells in the periphery and endometrium. Therefore, some uRPL cases have been explained by autoimmune abnormalities. The efficacy of intravenous immunoglobulin (IVIg) for uRPL has been confirmed in several clinical trials; however, its mechanism remains unknown, mainly because the abortion mechanism remains to be elucidated. In the present study, we analyzed the mechanisms of both abortion and IVIg action using a uRPL mouse model in which abortion was induced by lipopolysaccharide injection. IVIg attenuated the abortion rate in the uRPL model mice. The suppressive effect of IVIg was maximized by high dose administration early after lipopolysaccharide injection. Specifically, we discovered the presence of two distinct uterine NK (uNK) subsets: CD44(bright) and CD44(mid) In uRPL model mice, we observed an increase in the number of CD44(bright) uNK cells, while the CD44(mid) uNK subset remained unchanged. Furthermore, when abortion was reduced by IVIg administration, the cell number of the CD44(bright) uNK subset did not increase, which might allow differentiating pathological from normal uNK cells based on CD44 expression. Based on these results, we propose not only an effective administration protocol of IVIg to the uRPL model mice, but also a novel mechanism of abortion related to the increase in the CD44(bright) subset and of IVIg, which suppresses the increase of the CD44(bright) subset.
© 2016 by the Society for the Study of Reproduction, Inc.

Entities:  

Keywords:  IVIg; NK cells; abortion; recurrent pregnancy loss

Mesh:

Substances:

Year:  2016        PMID: 27335067     DOI: 10.1095/biolreprod.116.138438

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  3 in total

1.  Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial.

Authors:  Hideto Yamada; Masashi Deguchi; Shigeru Saito; Toshiyuki Takeshita; Mari Mitsui; Tsuyoshi Saito; Takeshi Nagamatsu; Koichi Takakuwa; Mikiya Nakatsuka; Satoshi Yoneda; Katsuko Egashira; Masahito Tachibana; Keiichi Matsubara; Ritsuo Honda; Atsushi Fukui; Kanji Tanaka; Kazuo Sengoku; Toshiaki Endo; Hiroaki Yata
Journal:  EClinicalMedicine       Date:  2022-06-29

2.  Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin.

Authors:  Julien Lion; Maren Burbach; Amy Cross; Karine Poussin; Cécile Taflin; Srini Kaveri; Alain Haziot; Denis Glotz; Nuala Mooney
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

3.  Histone deacetylase 9 deficiency exaggerates uterine M2 macrophage polarization.

Authors:  Yanqin Liu; Meirong Du; Hai-Yan Lin
Journal:  J Cell Mol Med       Date:  2021-06-19       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.